242 related articles for article (PubMed ID: 30499599)
1. The role of pathogen-reduced platelet transfusions on HLA alloimmunization in hemato-oncological patients.
Saris A; Kerkhoffs JL; Norris PJ; van Ham SM; Ten Brinke A; Brand A; van der Meer PF; Zwaginga JJ
Transfusion; 2019 Feb; 59(2):470-481. PubMed ID: 30499599
[TBL] [Abstract][Full Text] [Related]
2. Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: results from a randomized trial.
Norris PJ; Kaidarova Z; Maiorana E; Milani S; Lebedeva M; Busch MP; Custer B; Rebulla P
Transfusion; 2018 May; 58(5):1210-1217. PubMed ID: 29473173
[TBL] [Abstract][Full Text] [Related]
3. Risk of HLA antibody generation after receipt of Mirasol versus standard platelets in the MIPLATE randomized trial.
Kaidarova Z; Di Germanio C; Custer B; Norris PJ
Transfusion; 2023 Apr; 63(4):791-797. PubMed ID: 36840440
[TBL] [Abstract][Full Text] [Related]
4. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
[TBL] [Abstract][Full Text] [Related]
5. Platelet alloimmunization in multitransfused patients with haemato-oncological disorders.
Bajpai M; Kaura B; Marwaha N; Kumari S; Sharma RR; Agnihotri SK
Natl Med J India; 2005; 18(3):134-6. PubMed ID: 16130614
[TBL] [Abstract][Full Text] [Related]
6. Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
Saris A; Pavenski K
Transfus Med Rev; 2020 Oct; 34(4):250-257. PubMed ID: 33127210
[TBL] [Abstract][Full Text] [Related]
7. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components--a randomized trial.
Oksanen K; Kekomäki R; Ruutu T; Koskimies S; Myllylä G
Transfusion; 1991 Sep; 31(7):588-94. PubMed ID: 1891788
[TBL] [Abstract][Full Text] [Related]
8. Clinical aspects of platelet transfusions.
Murphy MF; Waters AH
Blood Coagul Fibrinolysis; 1991 Apr; 2(2):389-96. PubMed ID: 1893071
[TBL] [Abstract][Full Text] [Related]
9. Dominant immune response to HLA-B57/B58 molecules after platelet transfusion.
Coombs J; Ben Hassen L; Leclerc M; Tamagne M; Pannetier L; Khelfa M; Delorme A; Bocquet T; Maury S; Pirenne F; Ansart-Pirenne H; Vingert B
Transfusion; 2020 Dec; 60(12):2807-2814. PubMed ID: 33037638
[TBL] [Abstract][Full Text] [Related]
10. Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness.
Mishima Y; Tsuno NH; Matsuhashi M; Yoshizato T; Sato T; Ikeda T; Watanabe-Okochi N; Nagura Y; Sone S; Kurokawa M; Okazaki H
Transfus Apher Sci; 2015 Feb; 52(1):112-21. PubMed ID: 25467707
[TBL] [Abstract][Full Text] [Related]
11. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children].
Pereira J; Bronfman L; Bertín P; Marzouka E; Hidalgo P; Amaya S; Mezzano D
Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051
[TBL] [Abstract][Full Text] [Related]
12. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial.
van Marwijk Kooy M; van Prooijen HC; Moes M; Bosma-Stants I; Akkerman JW
Blood; 1991 Jan; 77(1):201-5. PubMed ID: 1984797
[TBL] [Abstract][Full Text] [Related]
13. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy.
Blundell EL; Pamphilon DH; Fraser ID; Menitove JE; Greenwalt TJ; Snyder EL; Repucci AJ; Hedberg SL; Anderson JK; Buchholz DH; Kagen LR; Aster RH
Transfusion; 1996 Apr; 36(4):296-302. PubMed ID: 8623127
[TBL] [Abstract][Full Text] [Related]
14. Platelet transfusion refractoriness due to HLA alloimmunization: Evolving paradigms in mechanisms and management.
Panch SR; Guo L; Vassallo R
Blood Rev; 2023 Nov; 62():101135. PubMed ID: 37805287
[TBL] [Abstract][Full Text] [Related]
15. Storage-Induced Platelet Apoptosis Is a Potential Risk Factor for Alloimmunization Upon Platelet Transfusion.
Saris A; Peyron I; van der Meer PF; Stuge TB; Zwaginga JJ; van Ham SM; Ten Brinke A
Front Immunol; 2018; 9():1251. PubMed ID: 29951051
[TBL] [Abstract][Full Text] [Related]
16. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness: a randomized prospective study.
Sintnicolaas K; van Marwijk Kooij M; van Prooijen HC; van Dijk BA; van Putten WL; Claas FH; Novotny VM; Brand A
Blood; 1995 Feb; 85(3):824-8. PubMed ID: 7833483
[TBL] [Abstract][Full Text] [Related]
17. In utero exposure to alloantigens primes alloimmunization to platelet transfusion in mice.
Poston JN; Jash A; Hannan LM; Hay AM; Usaneerungrueng C; Howie HL; Kapp LM; Zimring JC
Transfusion; 2021 Mar; 61(3):687-691. PubMed ID: 33336414
[TBL] [Abstract][Full Text] [Related]
18. [Platelet transfusion refractoriness and effective management of platelet alloimmunization].
Amemiya Y
Nihon Rinsho; 1997 Sep; 55(9):2392-8. PubMed ID: 9301306
[TBL] [Abstract][Full Text] [Related]
19. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
20. Use of HLA- and HPA--matched platelets in alloimmunized patients.
Kekomäki R
Vox Sang; 1998; 74 Suppl 2():359-63. PubMed ID: 9704468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
